Healthy volunteers test new drug combo absorption
NCT ID NCT07133399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial in 32 healthy adults compared how two different combinations of vicadrostat and empagliflozin are absorbed by the body. It also looked at whether food changes drug levels. Participants received a single dose of each combination in random order. The goal was to measure drug concentrations in the blood, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vicadrostat and empagliflozin combination
- What this could lead to
- If successful, this could help determine the best way to combine these two drugs for future studies.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures drug levels, not whether the drugs work for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test